Pancreatic cancer environment: From patient-derived models to single-cell omics

A Gu, J Li, S Qiu, S Hao, ZY Yue, S Zhai, MY Li… - Molecular …, 2024 - pubs.rsc.org
Pancreatic cancer (PC) is a highly malignant cancer characterized by poor prognosis, high
heterogeneity, and intricate heterocellular systems. Selecting an appropriate experimental …

[HTML][HTML] A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy

CWF van Eijck, S Sabroso-Lasa, GJ Strijk… - Neoplasia, 2024 - Elsevier
Background Pancreatic ductal adenocarcinoma (PDAC) is often treated with FOLFIRINOX, a
chemotherapy associated with high toxicity rates and variable efficacy. Therefore, it is crucial …

[HTML][HTML] Immunogenicity and Safety of COVID-19 Vaccines in Patients with Pancreatic Cancer

LV Wismans, RD de Vries, CWF van Eijck, M Verheij… - HPB, 2025 - Elsevier
Background Patients with pancreatic ductal adenocarcinoma (PDAC) are at increased risk
for severe COVID-19. Although COVID-19 vaccines are crucial for this population, studies on …